October 13, 2003 02:59 PM US Eastern Timezone
IMGENEX Now Offers Antibodies Against Severe Acute Respiratory Syndrome -SARS- Coronavirus Proteins
SAN DIEGO--(BUSINESS WIRE)--Oct. 13, 2003--Since its first appearance in November 2002, SARS coronavirus (SARS-CoV), identified as the causative agent of Severe Acute Respiratory Syndrome (SARS), has affected thousands of individuals and become a global concern. Coronaviruses, which are the major cause of upper respiratory tract illness and accounts for as much as 33% of all cases of the common cold, are positive stranded RNA viruses containing one of the largest viral RNA genomes known to date.
As one of the leading providers of antibodies, IMGENEX is proud to offer a panel of antibodies against SARS spike and nucleocapsid proteins. These two proteins are detected in culture supernatants of cells infected with SARS-CoV. At present, these highly sensitive antibodies are available for research use only. A number of PCR-based diagnostic tests are commercially available for detection of SARS virus. However, very few antibodies are available for studying expression of different SARS proteins in experimental systems.
"We believe IMGENEX antibodies will greatly facilitate research on SARS infection," said Jason Stampfl, director of Antibody Production at IMGENEX.
IMGENEX Corp. (www.imgenex.com) with offices in San Diego and Bhubaneswar, India develops and commercializes novel reagents for the scientific study of human biology and disease and for the production of new diagnostic assays and potential therapies of such diseases. These novel reagents include antibodies, gene and protein expression systems, arrays of various cells and tissues, and siRNA interference systems for use in studies of functional genomics. Areas of biological interest at IMGENEX include cancer, apoptosis (programmed cell death), molecular signaling pathways, cellular aging, and metabolic and infectious diseases.